Celyad Oncology Reports Full Year 2024 Financial Results and Recent Business Highlights
MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--April 02, 2025--
Regulatory News:
Celyad Oncology (Euronext: CYAD) (the "Company"), today announces its financial results for the fiscal year ended December 31, 2024, and provides a business update.
Matt Kane, Chief Executive Officer of Celyad Oncology, commented: "2024 was an important and highly productive year for the Company as it emerged with a lean and efficient new structure. I am incredibly proud of the resilience and ingenuity demonstrated by the team throughout the year."
2024 business highlights
-- Monetization of its innovative approaches and technologies is a key
objective. Celyad Oncology is progressing in this regard and is currently
in discussion with potential partners for selected out-licensing of its
technologies;
-- The Company continues to address current deficiencies in CAR-T
approaches. It has published a review highlighting non-gene editing
technologies for allogeneic CAR T-cell therapies in Cells1 and a review
providing an overview of engineering strategies to safely drive CAR
T-cells into the future in Frontiers in Immunology 2;
-- In response to the request expressed by several companies and academic
institutions engaged in gene and cell therapies for cardiac applications,
the Company has re-initiated the manufacturing and commercialization of
C-Cath$(R)$, an intra-myocardial injection catheter developed and owned by
the Company.
2024 operational highlights
-- Multiplex micro ribonucleic acid (miRNA)-based short hairpin RNA (shRNA)
non-gene edited technology platform
-- Last year, the company introduced a chimeric micro-RNA (miRNA)
cluster to enable multiplexing of shRNAs, and downregulation of up
to four target genes simultaneously in CAR T-cells. In 2024, we
further advanced this technology by expanding the platform to a
5-plex system. The novel chimeric cluster demonstrated high
efficiency in knocking down five highly relevant genes in CAR
T-cells simultaneously. Notably, our non-gene editing technology
enabled independent modulation of each target gene to achieve the
desired expression levels, thus fine-tuning the functional
outcomes based on the specific biology of each target.
-- The feasibility and effectiveness of our multiplex approach to
improve allogeneic CAR T-cell viability by avoiding
graft-versus-host disease (GvHD) and host-versus-graft (HvG)
reaction and promoting cell persistence was demonstrated.
Additionally, the feasibility of this platform to withstand the
immunosuppressive tumor microenvironment was further demonstrated.
Lastly, the secretion of specific cytokines was modulated as a way
to reduce the risk of CAR T-cell-related toxicity, and cytokine
release syndrome, thus enhancing CAR T-cell safety.
-- Multispecific NKG2D-based CAR T-cell platform
-- PSMA/NKG2DL tandem CAR T-cells, that encompass the extracellular
domain of the natural NKG2D receptor fused to an anti-PSMA CAR to
overcome antigen heterogeneity were developed and demonstrated
these CAR constructs are fully functional in vitro against
prostate cancer cell lines that are positive or negative for the
tumor-associated antigen PSMA. In vivo data confirmed the
superiority of both PSMA/NKG2DL tandem CAR T-cells and NKG2DL
single CAR T-cells over PSMA single CAR T-cells in a heterogeneous
model of prostate cancer. These data provide a proof-of-concept
that NKG2DL are valuable targets in a multispecific CAR approach
to treat solid cancer indications;
-- In addition, the in vivo proof-of-concept of the previously
developed CD19/NKG2DL tandem CAR T-cell candidate was provided in
a B-ALL relapse model, showing that the Company's multispecific
CAR T-cell candidate has an enhanced anti-tumor efficacy in a
lymphoma model of antigen-loss as compared to currently existing
treatment options.
Full year 2024 financial review
As of December 31, 2024, the Company's Treasury position amounts to EUR4.2 million.
The Company projects that its existing cash and cash equivalents should be sufficient to fund operating expenses and capital expenditure requirements into the third quarter of 2025. Hence, its existing cash and cash equivalents will not be sufficient to fund its estimated operating and capital expenditures over at least the next 12 months from the date that the financial statements are issued.
Refinancing discussions are ongoing.
Key financial figures for full-year 2024, compared with full-year 2023, are summarized below:
Selected key financial figures (EUR millions) Full year 2024 Full year 2023 -------------------------------------------- --------------- --------------- Revenue 0.2 0.1 -------------------------------------------- --------------- --------------- Research and development expenses (3.2) (4.6) -------------------------------------------- --------------- --------------- General and administrative expenses (3.2) (6.0) -------------------------------------------- --------------- --------------- Other income/(expenses) 0.4 2.1 -------------------------------------------- --------------- --------------- Operating loss (5.9) (8.5) -------------------------------------------- --------------- --------------- Loss for the period/year (5.8) (8.5) -------------------------------------------- --------------- --------------- Net cash used in operations (2.8) (15.2) -------------------------------------------- --------------- --------------- Treasury position (1) 4.2 7.0 -------------------------------------------- --------------- --------------- (1) "Treasury position" is an alternative performance measure determined by adding Short-term investments and Cash and cash equivalents from the statement of financial position prepared in accordance with IFRS. Management's purpose of this measure is to identify the level of cash available internally (excluding external sources of financing) within 12 months.
Research and Development (R&D) expenses were EUR3.2 million in 2024 as compared to EUR4.6 million in 2023, a year-over-year decrease of EUR1.4 million. The decrease in the Company's R&D expenses is primarily driven by the Company's continuous efforts to reduce significantly the preclinical and clinical costs following the change of business strategy by the Company end of 2022. Furthermore, employee expenses have decreased compared with the year 2023 as a consequence of the Company's reorganization for the new business model in 2022 and 2023.
General and Administrative (G&A) expenses were EUR3.2 million in 2024 as compared to EUR6.0 million in 2023, a decrease of EUR2.8 million. This decrease is primarily related to the decrease of insurances costs, the decrease of employee and consulting fees expenses due to headcount reduction and management changes.
Until December 31, 2024, Management has determined that there has been no event (such as a firm sublicense or collaboration contract) that led to a change in fair value of the contingent consideration and other financial liabilities towards Dartmouth and Celdara.
The Company's other income decrease of EUR1.9 million is mainly related to lower grants income from the Walloon Region of EUR0.8 million coupled to a one-time income of EUR1.1 million generated by the sale of certain fixed assets to Cellistic in 2023.
Net loss for the year ended December 31, 2024, was EUR5.8 million, or EUR0.14 per share, compared to a net loss of EUR8.5 million, or EUR0.34 per share, for the same period in 2023. As noted above, the decrease in net loss between periods was primarily due to the decrease of R&D and General and administrative expenses in 2024.
Net cash used in operations for the year ended December 31, 2024, which excludes non-cash effects, amounted to EUR5.7 million, which is far below the net cash used in operations of EUR15.2 million for the year ended December 31, 2023.
Alarm bell status
The net assets of the Company per 31 December 2024, on a BE-GAAP non-consolidated basis, having fallen below twenty-five percent of the Company's capital, the board of directors will submit to the ordinary shareholders meeting on the 20(th) of May 2025 the proposal to continue the Company's activities in accordance with article 7:228 of the Belgian Code for Companies and Associations. The board of directors will publish a special report in this respect, by the 18(th) of April 2024 together with the convening notice with proposed resolutions for the shareholders' meeting.
Annual Report 2024
The Annual Report for the year ended December 31, 2024 will be published on April 04, 2025, and will be available on the Company's website, www.celyad.com. The Company's statutory auditor, BDO Réviseurs d'Entreprises SRL, has confirmed that the completed audit has not revealed any material misstatement in the consolidated financial statements. BDO also confirmed that the accounting data reported in the press release are consistent, in all material respects, with the consolidated financial statements from which it has been derived.
Financial Calendar 2025
-- May 20th, 2025: Annual shareholders meeting -- September 25th, 2025: First Half 2025 Interim Results
The financial calendar is communicated on an indicative basis and may be subject to change.
About Celyad Oncology
Celyad Oncology is a cutting-edge biotechnology company dedicated to pioneering the discovery and advancement of revolutionary technologies for chimeric antigen receptor $(CAR)$ T-cells. Its primary objective is to unlock the potential of its proprietary technology platforms and intellectual property, enabling to be at the forefront of developing next-generation CAR T-cell therapies. By fully leveraging its innovative technology platforms, Celyad Oncology aims to maximize the transformative impact of its candidate CAR T-cell therapies and redefine the future of CAR T-cell treatments. Celyad Oncology is based in Mont-Saint-Guibert, Belgium. For more information, please visit www.celyad.com.
Celyad Oncology Forward-Looking Statement
This release may contain forward-looking statements, including, without limitation, statements regarding beliefs about and expectations for the Company's updated strategic business model, including associated potential benefits, transactions and partnerships, statements regarding the potential value of the Company's IP, statements regarding the Company's financial statements and cash runway, statements regarding the Company's future fundraising plans, statements regarding the Company's hiring plans, and statements regarding the continuation of the Company's existence. The words "will," "potential," "continue," "target," "project, " "should" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this release are based on management's current expectations and beliefs and are subject to a number of known and unknown risks, uncertainties and important factors which might cause actual events, results, financial condition, performance or achievements of Celyad Oncology to differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks related to the material uncertainty about the Company's ability to continue as a going concern; the Company's ability to realize the expected benefits of its updated strategic business model; the Company's ability to develop its IP assets and enter into partnerships with outside parties; the Company's ability to enforce its patents and other IP rights; the possibility that the Company may infringe on the patents or IP rights of others and be required to defend against patent or other IP rights suits; the possibility that the Company may not successfully defend itself against claims of patent infringement or other IP rights suits, which could result in substantial claims for damages against the Company; the possibility that the Company may become involved in lawsuits to protect or enforce its patents, which could be expensive, time-consuming, and unsuccessful; the Company's ability to protect its IP rights throughout the world; the potential for patents held by the Company to be found invalid or unenforceable; and other risks identified in the latest Annual Report of Celyad Oncology. These forward-looking statements speak only as of the date of publication of this document and Celyad Oncology's actual results may differ materially from those expressed or implied by these forward-looking statements. Celyad Oncology expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.
Source: Celyad Oncology SA
(1) Cells 2024;13(2):146
(2) Front Immunol. 2024:15:1411393
Celyad Oncology SA
Consolidated Statement of Comprehensive Loss
(EUR'000) For the year ended December 31
2024 2023
Revenue 186 102
Cost of sales (12) (69)
Gross profit 173 33
Research and Development expenses (3 235) (4 602)
General & Administrative expenses (3 198) (6 028)
Other income 440 2 334
Other expenses (39) (194)
Operating Loss (5 858) (8 457)
Financial income 153 30
Financial expenses (119) (84)
Loss before taxes (5 824) (8 511)
Income taxes 0 63
Loss for the period (5 824) (8 448)
Basic and diluted loss per share (in EUR) (0.14) (0.34)
------------------------------------------ --------------- ---------------
Celyad Oncology SA
Consolidated Statement of Financial Position
(EUR'000) For the year ended December 31
2024 2023
NON-CURRENT ASSETS 3 413 5 161
Goodwill and Intangible assets 405 390
Property, Plant and Equipment 1 493 1 830
Non-current Grant receivables 1 420 2 804
Other non-current assets 95 137
CURRENT ASSETS 6 515 11 121
Inventories 417
Trade and Other Receivables 170 457
Current Grant receivables 628 2 258
Other current assets 1 099 1 402
Cash and cash equivalents 4 200 7 004
TOTAL ASSETS 9 928 16 282
EQUITY 511 6 304
Share Capital 8 216 32 949
Other reserves 35 766 35 734
Capital reduction reserve 320 726 295 993
Accumulated deficit (364 196) (358 372)
NON-CURRENT LIABILITIES 6 571 7 046
Lease liabilities 763 902
Recoverable Cash advances (RCAs) 4 195 4 505
Post-employment benefits 1 1
Other non-current liabilities 1 612 1 638
CURRENT LIABILITIES 2 846 2 932
Lease liabilities 142 156
Recoverable Cash advances (RCAs) 639 366
Trade payables 1 233 1 243
Contract liabilities 46
Other current liabilities 786 1 167
TOTAL EQUITY AND LIABILITIES 9 928 16 282
--------------------------------- --------------- ---------------
Celyad Oncology SA
Consolidated Net Cash Burn Rate (1)
(EUR'000) For the year ended 31 December
2024 2023
Net cash used in operations (5 680) (15 202)
Net cash (used in)/from investing activities (103) 407
Net cash (used in)/from financing activities 2 983 9 355
Effects of exchange rate changes (4) (1)
Net cash burned over the period (2 800) (5 441)
-------------------------------------------- -------------- ----------------
(1) Net cash burn rate' is an alternative performance measure determined by the year-on-year net variance in the Group's treasury position as above defined. The purpose of this measure for the Management is to determine the change of the treasury position.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250402717539/en/
CONTACT: Investor & Media Contact:
David Georges, VP Finance and Administration
investors@celyad.com
(END) Dow Jones Newswires
April 02, 2025 13:00 ET (17:00 GMT)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.